Follow the chain left → right, from inputs to end demand. Tap any company to trace its links.
Raw inputs
Equipment
Foundry
Chip design
Software
AI demand
—
Company details
Market cap
$120B
P/E ratio
17×
Div yield
4.3%
Dividend/sh
$2.49
Profit margin
15%
Rev. growth
-1%
Revenue
$48B
Free cash flow
$13B
In plain English
Bristol Myers Squibb is a big-pharma giant racing its own patent cliff: its cash cows — the blood thinner Eliquis and cancer drugs from the $74B Celgene deal — are losing exclusivity, so it has spent ~$90B buying its way to a new pipeline (Karuna's schizophrenia drug Cobenfy, RayzeBio's radiopharmaceuticals, Mirati) to refill the tank while Opdivo and a fast-growing portfolio carry it forward.
In simple terms
What Bristol Myers Squibb really sells
Bristol Myers Squibb is a big-pharma giant racing its own patent cliff: its cash cows — the blood thinner Eliquis and cancer drugs from the $74B Celgene deal — are losing exclusivity, so it has spent ~$90B buying its way to a new pipeline (Karuna's schizophrenia drug Cobenfy, RayzeBio's radiopharmaceuticals, Mirati) to refill the tank while Opdivo and a fast-growing portfolio carry it forward.
Tip · Click any company in the map to learn — in one sentence — what it actually does and why it matters.